We present the case of an 18.5-year-old boy with hemophilia A and FVIII inhibitor detected at the age of 8 months. No persistent inhibitor eradication was achieved, despite three attempts of immune tolerance induction (ITI) with temporary inhibitor resolution and subsequent administration of 11 doses of rituximab. In spite of hemostatic treatment, rehabilitation, and radiosynovectomy, the patient suffered from recurrent bleeding episodes into almost all major joints, which resulted in the development of progressive hemophilic arthropathy. Currently, due to high frequency of bleeding episodes, the patient is being treated prophylactically and receives prophylaxis with activated prothrombin complex concentrate (aPCC).
Introduction
Hemophilia A is an inherited bleeding diathesis resulting from decreased FVIII plasma activity, predisposing to an increased frequency of spontaneous bleeding episodes, mainly into joints and muscles.
Hemophilia A patients receive intravenous concentrates of deficient clotting factor in order to treat bleeding episodes and prevent their reoccurrence. However, this management is associated with potentially negative immunological reaction to therapeutic FVIII due to possible development of anti-FVIII neutralizing antibodies (i.e., inhibitor).
The abovementioned problem is observed mainly in patients with severe hemophilia A with an inhibitor prevalence of 10%-33% [1, 2] .
A common therapy used in inhibitor eradication is immune tolerance induction (ITI) [3, 4] .
Case report
Difficulties associated with the abovementioned treatment are illustrated in the presented case of hemophilia A patient who developed FVIII inhibitor. The patient was born in May 1998 (gravida 1, normal para 1). He was first hospitalized at the age of 8 months due to bleeding into the buttock. The family history of bleeding diathesis was negative.
In a laboratory assessment of the patient's coagulation system, APTT was indeterminable and subsequent evaluation of FVIII levels revealed very low values (<1% of active factor) of this clotting factor. Therefore, the patient was diagnosed with severe hemophilia A. Further tests revealed mutation of FVIII in the form of intron 22 inversion.
From his first bleeding episode, the patient received on-demand FVIII concentrate in a dose of 30 U/kg of body weight (BW).
All preventive vaccinations were administered subcutaneously in association with the prophylactic use of FVIII concentrate. From the beginning of the treatment, inhibitor titer evaluation was performed during every three to five courses of FVIII concentrate therapy. At the age of 16 months, after 36 courses of FVIII concentrate, lack of hemostatic effect after FVIII treatment was stated. At that time, the FVIII inhibitor level was 6.5 BU/ml and was increasing progressively.
Next, the patient was implanted with a central venous catheter (Port-aCath) in order to initiate ITI and attempt to eradicate inhibitor (inhibitor titer was 17 BU/ml at the time). As part of the ITI regimen, the patient received FVIII concentrate daily in a dose of 200 U/kg BW for 10 months (from September 1999 until July 2000). Unfortunately, an increase of inhibitor titer to 28 BU/ml was observed. Due to lack of factor VIII supplies and lack of response to FVIII replacement therapy, the dose was modified to 150 IU/kg BW three times per week. Regrettably, the abovementioned regimen was also ineffective and did not result in inhibitor eradication. Thus, in December 2000, after 15 months of use, we decided to withdraw this therapy. However, the patient's situation was poor as he suffered from frequent hemarthroses and progressive arthropathy, which caused a significant decrease in his quality of life Owing to previous therapeutic failures, we decided to use on-demand sequential treatment with two bypassing agents only, recombinant activated factor VII (rFVIIa) and aPCC, instead of the previous regimen consisting of one bypassing agent administered during bleeding episodes.
Unfortunately, the abovementioned regimen was also ineffective.
In February 2005, after 6 years of hemophilia A treatment, when the patient was 7 years old, we decided to try another prophylactic regimen consisting of rFVIIa, however, this time, in trial conditions. rFVIIa was After a fifth dose of rituximab, inhibitor titer reduction to <0.4 BU/ ml was obtained. Therefore, subsequent doses were given only on demand (i.e., only in the case of an inhibitor titer increase). The regimen was used for 3 years until May 2012. In total, the patient received 11 doses of rituximab. Unfortunately, the initial positive outcome of rituximab therapy was not persistent. In October 2013, after 3 years of treatment, an abrupt inhibitor titer increase of >18 BU/ml was observed. Therefore, no 12th dose of rituximab was given ( Fig. 1) . This was also the reason for ITI regimen discontinuation.
At that time, the patient was suffering from frequent hemarthroses, again mainly into knee and elbow joints. Radiosynovectomy of these 
Discussion
The therapy of patients with hemophilia A is based on replacement of deficient clotting factor factor, in order to prevent or stop an active bleeding episode. In most cases, this approach is effective.
However, it may be associated with the risk of anti-FVIII antibody (the so-called inhibitor) development. Depending on the inhibitor level, this may limit the effectiveness of deficient coagulation factor concentrate administration [5, 6] . in hematological conditions, including hemophilia with treatmentresistant inhibitor [4] . Therefore, the abovementioned drug was given to our patients, yet the initial results of treatment were only temporary.
In the presented case with high inhibitor titer and joint bleeding episodes, we also used another treatment option, i.e., prophylaxis with bypassing agents. It is believed that prophylactic use of aPCC can be recommended to patients with persisting inhibitor and recurrent joint bleeding episodes, when previous ITI was ineffective.
This is also the case of patients not fulfilling criteria of ITI use and not giving their consent to this type of treatment.
Prophylactic use of aPCC reduces the number of bleeding episodes and may increase the effectiveness of ITI [7] .
Above we have summarized all the data that can be found in literature to date. However, the question of clinical practice remains. The case we describe here indicates that despite the use of different available methods and initial successes, inhibitor eradication is not persistent.
Moreover, because of the patient's young age and the consequences of recurrent joint bleeding episodes, this case is very dramatic.
Regrettably, recurrent joint bleeding episodes were the biggest problem. Perhaps, our decision on radiosynovectomy at the age of 9, when joint lesions are already significant (5 points on Pettersson scale), was made too late. Possibly, introduction of early, long-term prophylaxis with bypassing agents would be more effective.
A new therapeutic option for all hemophilia A with inhibitor is the use of Fc fusion technology (rFVIIIFc) to prolong circulation in the body.
Recombinant factor VIII Fc fusion protein demonstrated rapid time to tolerization in high-risk first-time ITI patients [8] .
Treatment of these disorders has focused on replacement of the missing coagulation factor to prevent or treat bleeding. New technologies and insights into hemostasis have driven the development of many promising new therapies for hemophilia and von Willebrand disease.
Emerging bypass agents including zymogen-like factor IXa and Xa molecules are in development, and a bispecific antibody, emicizumab, demonstrated efficacy in phase 3 trial in people with hemophilia A and inhibitors. Tissue factor pathway inhibitor, the protein C/S system, and antithrombin are targets of novel compounds in development to alter the hemostatic balance, and new approaches using modified factor VIII molecules are being tested for prevention and eradication of inhibitor antibodies in hemophilia A [9, 10] .
Results of the emicizumab test based on HAVEN 1-4 test are very promising [11, 12, 13] . Young reported an overall 99% reduction in the annualized number of treated bleeding events compared to the prior bypassing agent regimen [14] .
The benefits of emicizumab include bioavailability following subcutaneous administration, a long-acting effect allowing for reduced dosing frequency potentially as infrequent as once monthly, greater prophylactic efficacy, and benefits irrespective of the presence or absence of an inhibitor to FVIII. However, further investigations are needed.
Today, we have a problem finding correct answers to all these questions. Furthermore, we do not know whether widespread prophylactic use of recombinant coagulation factor concentrates will impact properties of newly developed inhibitors and our ability to eradicate them. Therefore, the search for new methods and treatment options for hemophilia patients with inhibitor is crucial. 
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